Lightnews — Scholar-powered news

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20d

Increasing access = increasing cost to increase sites, staff, etc. That is not the mode the government is currently in. Look into NCCCP and NCORP NCI programs for more background

1 1

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23d

Many publications on this. Short answer is 1) Improve access. 2) Remove I/E criteria that are not necessary. In the US ~85% of cancer patients are treated in the community setting. #ClinicalTrials

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Sep 11

Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Aug 22

1) The demographics of MM are usually elderly. 2) Patients are treated by oncologists who monitor side effects -- on or off a study.

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Aug 20

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Aug 20

Yes. Len and Dara-len are commonly used in MM therapy and tolerated

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jul 28

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

1 1 4

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jul 21

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

Reposted by Mike Thompson, MD, PhD, FASCO

Journal of Patient-Centered Research & Reviews @realjpcrr.bsky.social · Jul 16

NOW PUBLISHED!! JPCRR Vol. 12, Issue 3: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social

1 3 4

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jul 14

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

Evaluation and comparison of two commercially available targeted next- | OTT

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jun 13

Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @drglenweiss.bsky.social et al. OncoTargets and Therapy ow.ly/KtCZ30pBOTq #PrecisionMedicine

Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making Glen J Weiss,1 Brandi R Hoff,1 Robert P Whitehead,1 Ashish Sang...

ow.ly

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jun 13

Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jun 4

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer www.lungcancerjournal.info/article/S016... #lcsm #ImmunoOnc #PrecisionMedicine

DDR genes play a key role in detecting and repairing DNA damage and are crucial for maintaining the integrity of the genome [1]. Alterations in DDR genes are associated with genomic instability and in...

www.lungcancerjournal.info

1 3

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · Jun 4

Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 31

Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher

1 1 4

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 29

Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - X: @mtmdphd
- Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified

3

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO ow.ly/iyIe50Igxhe @myelomacrowd #mmsm

ASCO Publications

ow.ly

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 meetings.asco.org/abstracts-pr... #mmsm

3

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 - Landau et al. #ASCO25 #Abst 7508
meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx

3

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1 - Quach et al. #ASCO25 Abst 7504
meetings.asco.org/abstracts-pr... #mmsm

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · May 23

Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx